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ABSTRACT 
3-hydroxy-3methylglutaryl Coenzyme A reductase, 
the rate limiting enzyme of mevalonate pathway, 
generates, in addition to cholesterol, a range of prod- 
ucts involved in several biological functions: oligo- 
prenyl groups, dolichol and ubiquinone. The latter, in 
particular, participates in electron transport chain 
and, in turn, in tissue energy supply. The enzyme is 
inhibited by statins that, besides lowering choles- 
terolemia, seem to impair human energy-dependent 
myocardial functions (e.g. stroke volume, cardiac 
output, and contractile index). The modulation of 
heart contractile properties could be explained by the 
decrease of ventricle ubiquinone content and/or by 
putative changes in proportion of the different my- 
osin heavy chain isoforms. Since we previously dem- 
onstrated that chronic statin treatment modifies my- 
osin heavy chain isoform pattern in skeletal muscle 
impairing its functional properties, this work was 
aimed at investigating the effects of statin chronic 
treatment on both ventricle ubiquinone content and 
myosin heavy chain isoforms. Our results showed 
that simvastatin treatment leads to a reduced amount 
of rat ventricle ubiquinone and to β myosin heavy 
chain disappearance. Thus, statins which are pre- 
scribed to prevent cardiovascular disease, might in- 
duce cardiac metabolic and structural modifications 
whose functional implications on contractility are still 
to be established and carefully considered.   
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1. INTRODUCTION 
The 3-hydroxy-3-methylglutaryl Coenzyme A (HMGR) 
is the key and rate-limiting enzyme of mevalonate path- 
way which provides cells with vital bioactive compounds 
such as cholesterol, ubiquinone (CoQ), dolichol and 
prenyls [1]. In skeletal muscle, in particular, cholesterol 
is a structural entity of the T-tubular system [2]; CoQ is 
involved in electron transport during oxidative phos- 
phorylation, assuring the production of ATP needed for 
muscle contraction; oligoprenyl groups are necessary for 
post-translational modification of proteins involved in 
signal transduction pathway; lastly, dolichol is essential 
for N-linked glycosylation of proteins, such as the 
fusogenic proteins responsible for myoblast fusion into 
multinucleated syncitia [3]. 
As central regulator of cholesterol homeostasis 
HMGR is highly regulated: it undergoes short- and long- 
term regulations, the latter concerns the modulation of 
HMGR protein levels by several factors which include, 
among others, the transcription factor SREBP (Sterol 
Regulatory Element Binding Protein) and Insig (Insulin 
induced gene), able to affect the enzyme transcription 
and degradation as a function of intracellular sterol 
amount and in dependence on cholesterol uptake by 
LDLr (Low Density Lipoprotein receptor). In addition to 
being involved in the regulation of lipogenic genes, 
SREBP-1a and -1c were demonstrated to inhibit myo- 
blast-to-myotube differentiation and to induce in vivo 
and in vitro muscle atrophy through the expression of the 
transcriptional repressors BHLHB2 and BHLHB3. Both 
the proteins can affect the expression of several genes 
involved in muscle contraction and development [4].  
The well-established link between plasma cholesterol 
levels and coronary artery disease and the contribution of 
elevated plasma cholesterol, specifically Low Density 
Lipoprotein (LDL)-cholesterol, to other diseases in- 
cluding cancer, obesity and diabetes, have made control 
of plasma cholesterol a major health aim [5]. 
The decrease of cellular cholesterol synthesis leads to 
a homeostatic response involving up-regulation of cell- 
surface receptors that bind atherogenic LDL and Very 
Low Density Lipoproteins (VLDL). The reduction of 
plasma LDL-cholesterol accounts for the clinical utility 
of statins that competitively inhibit HMGR [6].  
Besides the benefits exerted on plasma lipid profile, 
statin treatment can lead to severe adverse effects on 
muscle tissues going from fatigue, weakness, and pain to 
symptoms associated to rhabdomyolysis, which is a life- 
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threatening condition [7].  
Although less investigated, statin side effects were de- 
tected also on cardiac muscle. Pisarenko and co-workers 
demonstrated that 1-month lovastatin therapy impairs 
human energy-dependent myocardial functions by de- 
creasing stroke volume, cardiac output, and contractile 
index. The authors ascribed the impairment of myocar- 
dium energy supply to the suppression of CoQ synthesis 
caused by statin treatment [8]. Although studies have 
repeatedly demonstrated a reduction of circulating CoQ 
concentrations with statin therapy, it is unclear whether 
tissue levels of CoQ are significantly affected [9].  
The modulation of the contractile properties of the 
heart could also be explained by putative changes in 
proportion of the different Myosin Heavy Chain (MHC) 
isoforms, α and β, that seem to be related to the level of 
mechanical performance of the heart [10]. Indeed, our 
previous work demonstrates that simvastatin chronic 
treatment (1.5 mg/kg/die) induces in rats functional im- 
pairment because of a shift of MHC isoforms from the 
fastest IIb to the slower IIa/x in fast skeletal muscle (Ex-
tensor digitorum longus) [3].  
Myosin is a major protein component of heart and 
skeletal muscles and is the element responsible for en- 
ergy transduction and force development in these tissues. 
Each myosin molecule contains four light chains and two 
heavy chains with ATPase activity. Ventricular muscle 
has three myosin isoforms that are designated, V1-3, in 
order of decreasing electrophoretic mobility and ATPase 
activity [11]. These isoforms differ only in their MHC 
composition. The V1 form is comprised of two α-MHCs, 
V3 has two β-MHCs, and V2 has one MHC of each type 
[10]. Differences in speed of contraction are well docu- 
mented for the ventricles and are correlated with varia- 
tions in the ratio of α to β-MHCs (reviewed in Swyng- 
hedauw, 1986 [12]). Fast-contracting ventricles (e.g., 
mice and rats) contain predominately the V1 form (αα); 
ventricles with intermediate speed (rabbit and guinea pig) 
are predominately V3 (ββ) but possess small amounts of 
the V1 and V2 (αβ) forms; slow ventricles (human and 
bovine) contain less than 10%V1 [10].  
Thus, owing to the ability of statins to impair skeletal 
muscle performance through a MHC isoform shift and to 
the inadequate knowledge about their capacity to reduce 
ventricular CoQ content, the aim of our research was to 
evaluate whether HMGR inhibition by simvastatin could 
modify ventricular CoQ9 (the predominant ubiquinone 
form in rats) content and could affect cardiac fiber phe- 
notype. 
2. MATERIALS AND METHODS  
2.1. Reagents  
All chemicals were obtained from commercial sources 
and were of the highest quality available; when the 
source is not specified they were obtained from Sigma- 
Aldrich (Milan, Italy).  
2.2. Animals 
3-months-old male Wistar Rattus norvegicus (Harlan 
Nossan, S. Pietro al Natisone, Italy) were housed under 
controlled temperature (20˚C ± 1˚C), humidity (55% ± 
10%), and illumination (lights on for 12 hours daily, 
from 7 a.m. to 7 p.m.). Food and water were provided ad 
libitum. The experiments were performed according to 
the ethical guidelines for the conduct of animal research 
(Ministero della Salute, Official Italian Regulation No. 
116/92, Communication to Ministero della Salute no. 
391/121). Rats were divided in two groups of 7 animals 
each. The first group was treated daily with intraperi- 
toneal injection of 1.5 mg/kg simvastatin in vehicle 
(dimethyl sulfoxide—DMSO—1 ml/kg) for 3 weeks. 
Control animals received daily an equal volume of 
vehicle. At the end of the treatment rats were anae- 
sthetized with urethane (1.2 g/kg) and plasma was ob- 
tained from blood collected into EDTA (1 mg/ml blood).  
The cardiac ventricles of the animals from each group 
were dissected and immediately frozen in liquid nitrogen 
for subsequent biochemical assays. 
2.3. Biochemical Analysis 
Plasma cholesterol and triglyceride analysis. Plasma cho- 
lesterol content of rats was assessed through the col- 
orimetric CHOD-POD kit according to manufacturer’s 
instructions (Assel, Rome, Italy). The amount of plasma 
triglycerides was measured by standardized commercial 
methods on a fully automated system (Modular, Roche, 
Basel Switzerland).  
Protein evaluation. Total lysates and Western blot ana- 
lysis were performed as already reported [3]. Primary 
antibodies used were β-MHC NOQ7.5.4D (Sigma-Al- 
drich), α-MHC BA-G5 (Abcam, Cambridge, UK), 
SREBP-1 (Santa Cruz Biotechnology, USA), vinculin 
and α-tubulin (Sigma-Aldrich).  
Lipid extraction and HPLC-UV analysis of polyiso- 
prenoids. These analyses were performed as already 
reported [3].  
3. RESULTS 
The systemic efficacy of simvastatin was verified by 
checking rat plasma cholesterol and triglyceride content. 
As expected, both the metabolic parameters were signifi- 
cantly decreased following statin treatment (Figure 1). 
HMGR chronic inhibition did not statistically modify 
animal weight (data not shown). 
The effects exerted by simvastatin in rat cardiac ven- 
tricles were investigated assessing the levels of HMGR 
main end-products namely cholesterol and CoQ9. Ven- 
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Figure 1. Plasma cholesterol and triglyceride content in rats 
treated with vehicle (DMSO) or simvastatin for 21 days. Data 
are expressed as mean ± SD of 7 different animals. *P < 0.05, 
***P < 0.001 as determined by Student’s t test. 
 
tricle cholesterol content was analyzed to ascertain whe- 
ther simvastatin was effective even in the heart; CoQ9 
amount was checked due to its implication in cardio- 
myocite energy supply. Tissue content of cholesterol was 
increased in cardiac ventricles of simvastatin-treated 
animals when compared to control rats (vehicle). On the 
contrary, the amount of ventricular CoQ9 was signifi- 
cantly reduced (Table 1). As further proof of simvastatin 
efficacy within cardiac ventricles, the protein levels of 
HMGR transcription factor SREBP-1 were assessed. As 
expected, the amount of transcriptionally active SREBP- 
1 fragment was significantly increased following sim- 
vastatin treatment (Figure 2(a)). 
Moreover, as we previously described that simvastatin 
was able to induce a shift of MHC isoforms in skeletal 
muscle [3] ventricular content of β-MHC was evaluated 
in order to investigate if simvastatin treatment could 
cause modification of MHC protein profile even in car-
diac muscle. Intriguingly, as shown in Figure 2(b), tis-
sue amount of β-MHC was strikingly reduced, on the 
contrary non-statistically significant differences were 
detected in ventricular α-MHC content of simvastatin- 
treated animals when compared to controls. 
4. DISCUSSION 
Our work highlights the strict connection between 
HMGR main end-products and cardiac physiology show- 
ing that the inhibition of the enzyme, which catalyzes the 
key and rate limiting step of cholesterol biosynthetic 
pathway, was able to reduce the amount of CoQ9 and 
β-MHC in rat ventricle. The enzyme activity was chroni- 
cally inhibited by means of simvastatin, among the lipo- 
philic statins generally taken up much more widely into a 
Table 1. Effect of simvastatin treatment on HMGR end-prod- 
ucts of the mevalonate pathway. Number of ventricles contrib- 
uting to each value are shown in brackets. **P < 0.01. 





(µg/g tissue) 106.56 ± 10.87 172.76 ± 6.88
** 0.0037 
CoQ9 
(µg/g tissue) 97.48 ± 5.45 58.12 ± 9.21
** 0.0081 
 
broad range of tissues compared with hydrophilic ones 
[13]. 
The lipid lowering property of simvastatin was dis- 
played by the reduction of both plasma cholesterol and 
triglyceride content. The efficacy of simvastatin on car- 
diac muscle was supported by the reduced amount of 
ventricular CoQ9 which guarantees the energy supply to 
the heart being involved in mitochondrial electron trans- 
port chain. On the contrary, tissue cholesterol levels in- 
creased. This result is not surprising if it is considered 
that statin treatment induces a compensatory up-regu- 
lation of the transcriptionally active fragment of SREBP- 
1 responsible for the expression of those genes involved 
in cholesterol uptake, among others LDLR.  
Given that fibers having distinct MHC isoforms ex- 
hibit different metabolisms and since an alteration in the 
energy metabolic system can affect cardiac gene expres- 
sion [14], we investigated whether the observed reduc- 
tion of ventricular CoQ9 content, following statin treat- 
ment, could cause putative modifications in the phenol- 
type of ventricular myocytes. Very interestingly, our 
hypothesis was confirmed by a strong reduction of β- 
MHC protein expression without any detectable modi 
fication in α-MHC content. These results seem appar- 
ently to contradict our previous data obtained from Ex- 
tensor digitorum longus muscle of simvastatin treated 
rats, where the statin induced a shift of fast MHC iso- 
forms towards a slower phenotype [3]. Actually, this 
discrepancy might be ascribed to the reduction of CoQ9 
(among the effectors of fiber oxidative metabolism) con- 
tent which occurs in rat heart but was not observed in rat 
skeletal muscle [3]. 
Moreover, MHC isoform pattern can be modulated by 
transcriptional repressors BHLHB2 and BHLHB3, both 
able to inhibit β-MHC expression more consistently than 
that of α isoform [4]. It is worth noting that both repres- 
sors are target genes of SREBP-1 which, as previously 
shown, increases following statin treatment. 
The hypothetical mechanism underlying the modifica- 
tion of fiber phenotype in cardiac ventricle of rats under 
statin treatment could depend on the homeostatic re- 
sponse of the tissue to HMGR inhibition: the rise of 
SREBP-1 active fragment can lead to a putative increase 
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(a)                                                  (b) 
Figure 2. SREBP1, α-MHC, and β-MHC in simvastatin treated cardiac ventricle. Panel a illustrates a typical West- 
ern blot (top) and the densitometric analysis (bottom) of SREBP1 detected in total lysates prepared from cardiac 
ventricle of rats undergone simvastatin treatment and those receiving vehicle. Panel b shows a representative West- 
ern blot (top) and the densitometric analysis (bottom) α-MHC and β-MHC detected in total lysates prepared from 
cardiac ventricle of rats undergone simvastatin treatment and those receiving vehicle. Protein levels were normal- 
ised to tubulin content. Data are mean values ± SD of seven different animals per group expressed as arbitrary units. 
*P < 0.05, **P < 0.001 as determined by Student’s t test. 
 
of BHLHB2 and BHLHB3 involved in β-MHC reduction. 
This event, together with the statin-induced decrease of 
CoQ9 content could cause a disproportion in fiber phe- 
notype inducing a shift towards a glycolytic metabolism.  
 OJMIP 
Since the different cardiac MHC isoforms exhibit dis- 
tinct functional characteristics and are distributed re- 
gionally within the heart to match the mechanical and 
functional demands of the different areas, Krenz and 
co-workers assess that even relatively minor changes in 
overall MHC isoform content could have significant 
functional consequences [15].  
In addition, we previously demonstrated that HMGR 
inhibition by simvastatin delays skeletal muscle regen- 
eration reducing myoblast fusion index and fast and slow 
MHC expression [16]. Thus, we cannot exclude that after 
myocardial infarction, when statins are always prescribed 
to patients, these drugs could further interfere with the 
already inefficient regeneration of cardiac tissue after 
injury.  
Our results seem to highlight a paradox: drugs such as 
statins, prescribed to prevent cardiovascular diseases, 
could cause cardiac metabolic and structural modifica- 
tions whose functional implications might be dangerous. 
In the light of our observations and of conflicting data 
present in literature, it is worthwhile investigating to 
what extent it is advantageous to prevent cardiovascular 
diseases through statin administration running the risk of 
undergoing myocardial function changes.  
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